Dunning commented, "I am excited to be involved in this important, growing segment of today's treatment landscape. With all the advances being made in health IT, there is not enough focus on streamlining the prescribing, distribution and administration of specialty drugs and biosimilars."
He added, "As healthcare experiences a shift from volume to value, and the growth of the specialty and biosimilar markets continue to outpace the traditional Rx market, I am fortunate to be joining the leader in this space."
ARx's evolving products, recently announced EHR partnerships and rapidly growing list of participating drugs spurred the company's search for an addition to the team with deep understanding of both the dynamic health IT space and the biopharmaceutical industry.
"It is very fortunate that we were able to find someone of Andrew's caliber to fulfill this role. His wealth of experience and industry knowledge has already made him a key addition to the AssistRx family," said Edward Hensley, Chief Commercial Officer of ARx. "We believe he can reinforce and grow our leadership position in the specialty drug market, and I'm confident that he will play a key role in partnering with our clients and implementing effective solutions for specialty drugs and biosimilars."
Founded in 2009, AssistRx is a leading healthcare information technology solutions and services organization dedicated to accelerating patient access to prescribed specialty medications. The company's cloud-based iAssist™ specialty medication services platform connects prescribers and patients to pharmaceutical and biotech manufacturer programs designed to speed time-to therapy and support medication adherence. To learn more, visit www.assistrx.com
Marketing & Communications Specialist
Amendola Communications for AssistRx
Logo - http://photos.prnewswire.com/prnh/20160307/341396LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/assistrx-appoints-new-vice-president-of-strategic-development-300240545.html